Adenocarcinoma of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Hcc-1 cDNA level was increased in pancreatic adenocarcinoma.
|
11356193 |
2001 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer.
|
24643682 |
2014 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer.
|
24643682 |
2014 |
Kidney Failure, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel CC chemokine, HCC-1, was isolated from the hemofiltrate of patients with chronic renal failure.
|
8551235 |
1996 |
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
A novel CC chemokine, HCC-1, was isolated from the hemofiltrate of patients with chronic renal failure.
|
8551235 |
1996 |
Chronic kidney disease stage 5
|
0.010 |
Biomarker
|
disease |
BEFREE |
A novel CC chemokine, HCC-1, was isolated from the hemofiltrate of patients with chronic renal failure.
|
8551235 |
1996 |
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
A novel protein, Hcc-1, was identified by analysis of the hepatocellular carcinoma (HCC)-M cell proteome.
|
11356193 |
2001 |
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
A total of 7 studies, which included 3 studies for breast cancer, 2 for colorectal cancer, 1 for hepatocellular carcinoma, 1 for esophageal cancer and 1 for Non-Hodgkin lymphoma.
|
25524946 |
2015 |
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 7 studies, which included 3 studies for breast cancer, 2 for colorectal cancer, 1 for hepatocellular carcinoma, 1 for esophageal cancer and 1 for Non-Hodgkin lymphoma.
|
25524946 |
2015 |
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
A total of 7 studies, which included 3 studies for breast cancer, 2 for colorectal cancer, 1 for hepatocellular carcinoma, 1 for esophageal cancer and 1 for Non-Hodgkin lymphoma.
|
25524946 |
2015 |
Schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among primates, a tyrosine hydroxylase (THO1) intron STR, previously implicated in both schizophrenia and drug withdrawal delirium, exhibited frequent replacements.
|
15656986 |
2005 |
Delirium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among primates, a tyrosine hydroxylase (THO1) intron STR, previously implicated in both schizophrenia and drug withdrawal delirium, exhibited frequent replacements.
|
15656986 |
2005 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
|
24972258 |
2014 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results indicate that LEF1-upregulated miR-HCC1 functions as an oncogene through the negative regulation of NFIX expression, which links the LEF1/miR-HCC1/NFIX axis to contribute to cell proliferation, migration and invasion of HCC cells and could provide novel insights into miRNA function and hepatocarcinogenesis and potential biomarkers for HCC.
|
29472529 |
2018 |
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, these results indicate that LEF1-upregulated miR-HCC1 functions as an oncogene through the negative regulation of NFIX expression, which links the LEF1/miR-HCC1/NFIX axis to contribute to cell proliferation, migration and invasion of HCC cells and could provide novel insights into miRNA function and hepatocarcinogenesis and potential biomarkers for HCC.
|
29472529 |
2018 |
Hepatocarcinogenesis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, these results indicate that LEF1-upregulated miR-HCC1 functions as an oncogene through the negative regulation of NFIX expression, which links the LEF1/miR-HCC1/NFIX axis to contribute to cell proliferation, migration and invasion of HCC cells and could provide novel insights into miRNA function and hepatocarcinogenesis and potential biomarkers for HCC.
|
29472529 |
2018 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
Cholangitis, Sclerosing
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
Primary sclerosing cholangitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
Hepatitis C
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of serum samples with different status of HBV and HCV infections suggested that HCc(1-98) might be suitable for the determination of antibodies against HCV core protein, while HBcPreS1PreS2HCc(1-98) might be of value to detect HCV and/or HBV infection in donated blood in HBV low-prevalence countries.
|
9892392 |
1999 |
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
Evaluation of serum samples with different status of HBV and HCV infections suggested that HCc(1-98) might be suitable for the determination of antibodies against HCV core protein, while HBcPreS1PreS2HCc(1-98) might be of value to detect HCV and/or HBV infection in donated blood in HBV low-prevalence countries.
|
9892392 |
1999 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the role of SARNP in mRNA splicing and export and in the progression of breast cancer, especially of TNBC, remains unknown.
|
31313837 |
2020 |
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the role of SARNP in mRNA splicing and export and in the progression of breast cancer, especially of TNBC, remains unknown.
|
31313837 |
2020 |